Profund Advisors’s Immunovant IMVT Stock Holding History

Profund Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.52M	Buy	61,008 +11,932	+24%	+$309K	0.06%	246
2025 Q4	$1.25M	Buy	49,076 +26,810	+120%	+$598K	0.04%	297
2025 Q3	$359K	Sell	22,266 -170	-0.8%	-$2.75K	0.01%	655
2025 Q2	$359K	Sell	22,436 -6,124	-21%	-$92.6K	0.01%	596
2025 Q1	$488K	Buy	28,560 +5,850	+26%	+$122K	0.02%	480
2024 Q4	$563K	Sell	22,710 -7,321	-24%	-$208K	0.02%	456
2024 Q3	$856K	Buy	30,031 +3,891	+15%	+$115K	0.03%	365
2024 Q2	$690K	Sell	26,140 -18,864	-42%	-$537K	0.03%	398
2024 Q1	$1.45M	Buy	45,004 +7,544	+20%	+$275K	0.06%	242
2023 Q4	$1.58M	Sell	37,460 -12,409	-25%	-$457K	0.07%	233
2023 Q3	$1.91M	Buy	49,869 +4,115	+9%	+$93K	0.11%	155
2023 Q2	$868K	Sell	45,754 -14,735	-24%	-$275K	0.05%	347
2023 Q1	$938K	Buy	+60,489	New	+$1.05M	0.06%	316

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Profund Advisors's IMVT Position: Q1 2026 in Review

Profund Advisors increased its Immunovant (IMVT) stake by 24% in Q1 2026, buying an estimated $309K and bringing the position to 61,008 shares worth $1.52M. The position accounts for 0.06% of the portfolio, ranked #246.

Profund Advisors first reported a position in IMVT in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.91M in Q3 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Profund Advisors held 61,008 shares of Immunovant worth $1.52M as of Q1 2026.
Profund Advisors bought 11,932 Immunovant shares in Q1 2026, an estimated $309K.
Immunovant made up 0.06% of Profund Advisors's portfolio in Q1 2026, its #246 holding.
Profund Advisors first reported a position in Immunovant in Q1 2023 and has held it in 13 quarters since.
Profund Advisors's Immunovant position peaked at $1.91M in Q3 2023.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.